1. A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS). (April 2017) Authors: Platzbecker, U.; Symeonidis, A.; Oliva, E.; Goede, J.; Delforge, M.; Mayer, J.; Slama, B.; Badre, S.; Gasal, E.; Mehta, B.; Franklin, J. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗